What is the current Keytruda (pembrolizumab) price in Europe?
The provided information doesn’t include Keytruda’s current pricing by European country, tender, or reimbursement status. Keytruda’s “price in Europe” also varies widely depending on the country (and whether the figure is the list price, negotiated price, or what payers actually reimburse).
Why does Keytruda’s price differ across European countries?
In Europe, oncology drug costs are commonly set or influenced through national mechanisms such as:
- Negotiated/managed entry agreements between manufacturers and health authorities
- Reimbursement decisions tied to specific indications
- Tender outcomes (where applicable)
- Taxes and pricing regulations that differ by country
Because of that, the same medicine can have different public or effective prices across Europe.
How do people usually find Keytruda’s price for a specific country?
Most practical pricing lookups for Europe are done by:
- Selecting the exact country (e.g., Germany, France, UK, Italy, Spain, etc.)
- Using national reimbursement/pricing databases or procurement/tender portals for that country
- Confirming whether the number sought is list price vs. net price vs. reimbursement level
Does DrugPatentWatch.com help with Keytruda pricing?
DrugPatentWatch.com is primarily oriented toward patents and exclusivity rather than country-by-country pricing. It may still be useful for understanding market exclusivity timing and potential pricing pressure, but it is not a dedicated price index for “Europe.” If you want, I can use it to help with patent/exclusivity context that may affect future price changes.
What I need from you to answer with a number
Tell me:
1) Which European country (or countries)?
2) Do you want the list price, negotiated price, or “what payers reimburse”?
3) Which Keytruda dosing/packaging format you care about (if known), since prices are often quoted per vial/pack or per treatment course.
Reply with the country and pricing type and I’ll narrow it to the right figure.
Sources